Artoflex is primarily used for the symptomatic management of pain, inflammation, and fever, offering supportive relief across several therapeutic domains.

The medication is applied in conditions characterized by periods of heightened symptoms, assisting in addressing pain and swelling. It is considered relevant for managing symptom clusters in conditions such as Osteoarthritis and other degenerative joint diseases; primary dysmenorrhea (menstrual cramps); and for easing manifestations of mild to moderate pain, including headache and dental pain.

It is often used when symptoms intensify, providing assistance that may support the patient during difficult episodes and assist with maintaining functional stability. For patients coping with chronic joint conditions or recovering from injury, it may support easing the overall symptom load.

“This medication is considered relevant for managing symptoms that create noticeable physiological strain and may interfere with daily comfort.”

---

Quick Fact: Relief for Pain and Inflammation

Category	Description
Symptom Domain	Pain (mild to moderate), Inflammation, and Fever
Primary Use	Supportive symptomatic relief in musculoskeletal conditions
Contextual Use	Acute pain, episodic discomfort, and febrile states
Core Benefit	Helps ease symptom burden and supports comfort

Eligibility Map: Who can and cannot use Artoflex — official regulatory information

Artoflex (Dexibuprofen) eligibility is strictly defined by regulatory documents, distinguishing between approved populations, those for whom use is restricted, and those absolutely contraindicated.

Populations Excluded (Contraindicated)

The medicine is contraindicated and must not be used by:

• Patients with hypersensitivity to dexibuprofen or any other NSAID (e.g., aspirin), or those who experience asthma or urticaria from them.
• Individuals with active or a history of recurrent peptic ulceration or gastrointestinal bleeding.
• Patients with severe heart failure, severe renal dysfunction (GFR < 30 ml/min), or severely impaired hepatic function.
• Women who are in the third trimester of pregnancy (from the beginning of the 6th month).
• Patients recovering from coronary artery bypass graft (CABG) surgery (for perioperative pain).

Populations with Restricted or Non-Recommended Use

• Children and Adolescents: Use is not recommended as safety and efficacy have not been established.
• Older Adults (The Elderly): Use requires special caution and monitoring due to an increased risk of serious gastrointestinal reactions.
• Pregnancy (First and Second Trimester): Use should be avoided unless clearly necessary; dosage must be minimal and duration short.
• Mild Organ Impairment: Patients with mild to moderate renal or hepatic dysfunction require appropriate monitoring.

---

Connection to the Eligibility Profile

The official documents establish that standard use is limited to Adults, while primarily defining eligibility boundaries through a comprehensive list of absolute contraindications related to organ failure, high GI risk, and specific physiological states.

The official regulatory documentation for Artoflex (Dexibuprofen) outlines specific interaction patterns with other medicines and products, focusing on changes in drug exposure and additive risks.

Official Interaction Statements

Classification	Interacting Agents and Documented Effect
Avoidance Required	Concomitant use with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, is to be avoided due to an increased risk of gastrointestinal (GI) ulceration and hemorrhage.
Exposure Elevation	Dexibuprofen reduces the renal clearance of high-risk drugs such as Lithium and Methotrexate (doses ge 15 mg/week), which results in elevated plasma levels and potential toxicity. This combination is generally not recommended.
Additive Risk	The risk of GI bleeding is increased when co-administered with oral corticosteroids, Anticoagulants (e.g., Warfarin), or Selective Serotonin Re-uptake Inhibitors (SSRIs).
Pharmacodynamic Interference	Dexibuprofen may diminish the blood pressure-lowering effect of antihypertensive agents, including ACE inhibitors and ARBs, and can reduce the antiplatelet effect of low-dose Acetylsalicylic acid (Aspirin).

Interaction Constraints

To mitigate potential interference with the antiplatelet effect of immediate-release Acetylsalicylic acid, regulatory data suggests timing separation: Dexibuprofen should not be administered within 8 hours before or 30 minutes after the aspirin dose. Furthermore, co-administration with diuretics or ACE inhibitors requires caution, particularly in elderly or volume-depleted patients, due to the heightened risk of renal function deterioration. Use with alcohol is noted to increase the risk of GI bleeding.

The mechanism of Dexibuprofen (Artoflex) is defined by a precise intervention in the Prostaglandin signaling network. It is delivered exclusively as the active S(+) enantiomer, which ensures a direct and specific interaction at the molecular level.

Inhibition of Prostaglandin Synthesis

This domain covers the drug’s primary biological targets: the Cyclooxygenase ( COX) enzymes. By acting as a reversible, competitive inhibitor, Dexibuprofen blocks COX-1 and COX-2 activity, thereby suppressing the conversion of Arachidonic Acid into various Prostaglandin mediators . This suppression initiates the mechanistic cascade that modulates Prostaglandin-mediated signaling.

️ Dual Modulation of Peripheral and Central Mechanisms

The mechanism exerts effects in two distinct physiological areas: local tissue sites and the central nervous system ( CNS). Peripherally, it reduces the Prostaglandin-mediated sensitization of pain-sensing neurons and minimizes inflammatory vascular responses. Centrally, it targets the hypothalamus, engaging the thermoregulatory pathway to facilitate the physiological adjustment of the elevated core body temperature.

---

This mechanism leads to predictable physiological adjustments that shape the drug's activity profile by modulating Prostaglandin signaling across the nervous system and vascular tissues.

General Administration Guidelines

The usage of Artoflex, which contains the active ingredient Dexibuprofen, follows established protocols focusing on the route, dosing, and schedule. The medicine is designated for oral administration as a film-coated tablet. The fundamental principle guiding its use is to administer the lowest effective dose for the shortest duration necessary to address the symptoms.

---

Official Dosing and Frequency

The standard adult daily dose for most indications is 600 mg of Dexibuprofen. The medicine may be taken up to three times daily, with the total dose divided and administered with an interval of at least 4 to 6 hours between doses. A maximum single dose of 400 mg must not be exceeded, and the maximum total daily intake is limited to 1200 mg. For situations requiring intensive control, the dosage may be transiently increased up to this maximum limit.

---

Contextual Use and Adjustments

Artoflex can be taken with or without a meal, though administering the tablet with food is often preferred to reduce the potential for gastrointestinal upset. While no specific dose changes are uniformly required for older adults (65+), therapy may be started at the lower end of the dosage range. For patients with mild to moderate renal or hepatic impairment, the starting dose is reduced and closely monitored.

Research evidence / Overview of Studies for Artoflex

Evidence for Use in Osteoarthritis and Joint Pain

This section summarizes the structure of randomized controlled trials (RCTs) that have evaluated the medicine in studies examining symptomatic measures of pain and function in adults with joint conditions. The studies were typically short-term, randomized, and controlled trials, comparing the medicine to either an inactive substance or another active medicine.

What remains notable is that the follow-up durations were often limited. Long-term effects are not fully established for the compound itself, requiring regulatory reliance on extrapolation from the broader Ibuprofen class for extended periods of use.

Evidence for Use in Primary Dysmenorrhea

This overview outlines the short-term, acute clinical trial designs, including controlled and crossover studies, used by researchers to study the medicine’s research base for visceral pain relief in women. These studies focused on measuring outcomes describing episodic or acute changes, such as the total pain relief achieved over a short period.

The evidence structure is heavily weighted toward acute, short-term relief. Consequently, the research provides limited insight into outcomes beyond the immediate, acute phase, and data for groups such as the younger adolescent population remain insufficient.

Evidence for Use in Acute Pain and Fever

This summary describes the research landscape covering acute pain models (such as post-operative pain) and comparative studies focused on tracking temperature change. Research examined comparative studies in children with fever and monitored outcomes related to systemic or functional imbalance.

Some systematic reviews note that while evidence exists from standard trial models, the sample sizes were modest in specific acute pain contexts, meaning evidence quality varies across studies, and results apply only to the populations studied.

Areas of Scientific Uncertainty and Research Gaps

One significant area of uncertainty involves the long-term safety profile, especially regarding the cardiovascular system, as long-term effects are not fully established. Furthermore, research has explored patterns of interaction when the medicine was studied for use alongside a common heart medicine. However, comparative evidence is lacking to fully clarify the clinical significance of this interaction pattern, and research is ongoing.

Common questions about Artoflex (FAQ)

---

Q: How long does it usually take to feel the effects of Artoflex?

Official product information indicates that the active ingredient is generally absorbed quickly. Peak concentrations in the body are typically reached within approximately one to two hours after the medicine has been administered. This timing is a general pharmacokinetic property shared by this class of medicine.

---

Q: Are there any documented cases of Artoflex affecting sleep?

Regulatory documents for this class of medicine state that adverse reactions reported by patients can include central nervous system (CNS) effects. Specifically, both insomnia (difficulty sleeping) and somnolence (drowsiness) have been reported among patients using the medicine.

---

Q: What does 'contraindicated' mean in the context of Artoflex eligibility?

According to regulatory and medical glossaries, a medicine is contraindicated when using it carries a risk that clearly outweighs any potential benefit. This indicates the medicine should not be used under those specific health conditions or circumstances listed in the eligibility map, such as severe organ failure or active bleeding.

---

Q: Are there any specific foods to avoid when using Artoflex?

Official documents state that there are no specific foods that must be avoided when using this medicine. While Artoflex can be taken with or without a meal, taking it with food is often noted as a way to potentially reduce the chance of experiencing stomach upset.

---

Q: How do studies describe the duration of Artoflex's effect?

Studies and official information on the medicine’s properties show that the active component has a relatively short half-life, typically reported to be between 1.8 to 3 hours in adults. This pharmacokinetic measure is part of the information used by regulatory bodies to determine the appropriate dosing frequency.

---

Q: Why is Artoflex sometimes described as an 'immunosuppressant'?

The medicine is officially classified as an Anti-inflammatory drug, not an immunosuppressant. Regulatory documents do, however, note potential interaction risks when taken with certain immune suppressants, such as Methotrexate, which may be a source of the confusion.

---

Q: Can Artoflex affect the results of common blood tests?

Official labeling for this class of medicine indicates that it can potentially affect the results of some laboratory tests. Reports have included abnormal findings in liver function tests and decreases in blood count measures like hemoglobin and hematocrit.

---

Q: Does Artoflex have a 'Black Box Warning' in the US?

Yes. Products in the Non-Steroidal Anti-Inflammatory Drug (NSAID) class, which includes the active ingredient of Artoflex, carry an FDA Boxed Warning. This warning notes the risk of serious cardiovascular events (like heart attack or stroke) and serious gastrointestinal issues (like bleeding or perforation).

---

Q: What does the term 'therapeutic window' mean for Artoflex?

The therapeutic window is a concept referring to the range of drug doses or concentrations that can effectively treat a condition while remaining below a level that causes unacceptable toxicity or side effects. This range is used by regulatory bodies when reviewing and defining the appropriate dose range for a medication.

---

Q: Is Artoflex considered a specialty medication?

Regulatory classification documents define the medicine as an Anti-inflammatory and a Non-Steroidal Anti-inflammatory Drug (NSAID). While official documents classify its pharmacological group, the designation of a medicine as a 'specialty medication' is typically determined by non-regulatory bodies, such as insurance providers or health systems.

---

Q: Does taking Artoflex affect fertility?

Official regulatory information for this class of drug states that the use of NSAIDs is associated with a potential for reversible infertility in women. Official documents suggest that the possibility of temporarily discontinuing the medicine should be discussed when women are experiencing difficulties conceiving.

---

Q: What does the term 'pharmacovigilance' mean for a drug like Artoflex?

Pharmacovigilance is the system used by regulatory agencies globally to monitor the safety of medicines after they have been authorized for use. It involves the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems associated with the product.

---

Q: Is Artoflex known to cause changes in mood or anxiety?

Official product labeling for this medicine class includes reports of psychiatric and central nervous system adverse reactions. These reported effects include experiences of anxiety and emotional lability, which refers to noticeable mood swings.

---

Q: How quickly is Artoflex eliminated from the body?

Official information states that the elimination of the active ingredient from the body is rapid. The component is typically virtually completely excreted, primarily through the urine, within 24 hours after a person takes the last dose.

---

How to Store and Dispose of Artoflex?

This medicine must be stored strictly according to the conditions defined in the official labeling, which typically ensures the product remains stable for its 2- to 3-year shelf life. Artoflex tablets must be kept at a temperature below 25 C and should be stored in the original container to protect them from moisture and light. It is a mandatory regulatory requirement to keep the product out of the sight and reach of children.

Disposal Requirements

Expired or unused Artoflex must be disposed of in accordance with local requirements. The product should not be disposed of via household waste or flushed down the toilet or sink, unless specific official instructions advise otherwise. Unused medication should generally be returned to a pharmacy or an approved collection point for safe disposal.